AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00715962 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Behavioral intervention
Description: Using social cognitive theory, participants in the walking program group will be encouraged to complete a brief diary about out of bed activities like sitting up for meals of walks to the bathroom. They will be provided with information regarding the importance of being out of bed a praise for any attempts. They will be asked to set out of bed time activity goals daily. The control group will have a diary to track visitors.
Study NCT00715962 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Walking Intervention
Description: Participants in the walking program will be assisted to walk twice a day by trained staff. Those in the control group will be visited twice a day for friendly visits only
Study NCT00715962 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Friendly visits
Description: The control group will receive twice daily friendly visits and will be asked to complete a diary each day of the people who visit them in the hospital.
Study NCT03938545 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RVT-1401 (Administered via subcutaneous injection)
Description: RVT-1401 is a fully human anti-neonatal Fc receptor (FcRn) monoclonal antibody.
Study NCT03938545 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo (Administered via subcutaneous injection)
Description: Placebo
Study NCT00816400 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-575
Description: MEDI-575 as an IV infusion
Study NCT03116737 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Benzocaine Otic Solution
Study NCT03116737 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT03468231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sorafenib
Description: Oral Sorafenib, 400mg, Bid
Study NCT03468231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sorafenib
Description: Oral Sorafenib, 400mg, Bid
Study NCT03468231 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: HAIC of FOLFOX
Description: administration of Oxaliplatin , fluorouracil, and leucovorin via the tumor feeding arteries
Study NCT03468231 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HAIC of OXA
Description: administration of Oxaliplatin via the tumor feeding arteries
Study NCT02511548 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Financial incentive
Description: Financial incentive will be proposed to participant of the intervention arm
Study NCT03237637 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: oral propranolol
Description: oral propranolol 1-2mg/kg/day as crushed tablets in two divided doses
Study NCT03237637 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: oral atenolol
Description: oral atenolol 0.5-1mg/kg/day as crushed tablets in a single dose
Study NCT00819962 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Bupivacaine
Description: Local anesthetic
Study NCT00819962 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: TAP
Study NCT03508037 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Neuromodulation electroencephalographic signals and functional electrical stimulation based
Description: First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
Study NCT03508037 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Neuromodulation electroencephalographic signals and functional electrical stimulation based
Description: First, the subject performs twenty reaching movements without assistance with the damaged arm resting on a robot (ArmeoSpring), with the aim of finding the Contingent Negative Variation (CNV). Then, he or she executes five courses of twenty movements receiving functional electrical stimulation (FES), either at the moment in which he or she wishes to move (experimental group), or half a second before or after (control group).
Study NCT04843553 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Oral Nicotinamide
Study NCT04843553 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Oral Nicotinamide
Study NCT00284817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 1 mg/kg for 51 weeks.
Study NCT00284817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; 4 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
Study NCT00284817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; 6 mg/kg on Study Day 0 followed by weekly maintenance doses of 2mg/kg for 51 weeks.
Study NCT00284817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: Administered as a 30-minute IV infusion; on Study Day 0 followed by weekly maintenance doses of 3mg/kg for 51 weeks.
Study NCT00284817 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MEDI-522
Description: The next cohort of patients will be treated after at least 3 of 4 patients treated in the previous cohort receive at least 3 weeks of treatment and experience no dose-limiting toxicity (DLT).
Study NCT02856828 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: DIE
Description: digital image enhancement
Study NCT01662726 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Irosustat
Description: Irosustat will be administered once daily in 40mg tablets. Treatment will start the day after the baseline FLT-PET and will be continued for a minimum of 2 weeks until the follow up FLT PET scan. For those patients who have consented to a repeat tumour biopsy, treatment will be extended to the day before the procedure. Study medication should be taken in the morning under fasting conditions with a glass of water, 30 minutes before breakfast.
Study NCT02010008 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Motivational Interviewing Intervention
Description: An individual-level intervention that implements a motivational interviewing intervention led by a promotora
Study NCT04566926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: JNJ-64140284
Description: Participant will receive JNJ-64140284 formulation 1 or 2 under fasting or fed condition.
Study NCT04566926 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Participant will receive matching placebo.
Study NCT01773291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: acupuncture
Description: acupuncture on GV26 and 12 Well points
Study NCT01773291 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: laser acupuncture
Description: laser acupuncture on GV26 and 12 Well points
Study NCT01773291 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: control
Description: sham laser acupuncture
Study NCT03597074 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: color Doppler Ultrasound derived RI and semi-quantitative evaluation of intra-renal vascularization
Description: Use of color Doppler Ultrasound derived Renal Resistive Index (RI) and semi-quantitative evaluation of intra-renal vascularization for early prognosis of AKI progression
Study NCT00901186 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: RFB002
Description: 0.5 mg
Study NCT00901186 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Laser photocoagulation
Study NCT02943486 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: dac-MSCs
Description: Cell-free therapy
Study NCT02943486 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: MSCs
Description: Cell-based therapy
Study NCT04536558 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: olanzapine plus fosaprepitant-based triple regimen
Description: olanzapine 5mg p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
Study NCT04536558 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo plus fosaprepitant-based triple regimen
Description: placebo p.o. on day 1-day 5, fosaprepitant 150mg i.v. on day 1 before undergoing chemotherapy. Patients received ondansetron hydrochloride(8mg, i.v. day 1-day 3) and dexamethasone(6mg, oral, day 1-day 5) at the same time, before undergoing chemotherapy.
Study NCT01134185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: single oral dose of 2 mg prucalopride
Study NCT01134185 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: prucalopride
Description: single dose of 2 mg prucalopride
Study NCT02242773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Multi-Parametric MRI
Description: Multi-Parametric MRI
Study NCT02242773 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: MRI-Guided Biopsy
Description: MRI-Guided Biopsy
Study NCT02943486 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Fitostimoline
Description: Triticum vulgare
Study NCT02943486 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fitostimoline
Description: Triticum vulgare
Study NCT01201317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 20 mg tablet
Study NCT01201317 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: AZD2423
Description: 150 mg tablet
Study NCT01201317 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo
Study NCT00679237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: smoking cessation
Description: NRT and varenicline
Study NCT00679237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: betablocker, diuretics, ACEI, ARB,
Description: blood pressure control according to ESC guidelines
Study NCT00679237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: statins, ezetimibe
Description: Cholesterol reduction according to ESC guidelines
Study NCT00679237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: training
Description: daily walking
Study NCT00679237 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: influenza vaccine
Description: vaccine (FLuarix, Influvac etc)
Study NCT00679237 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: metformin, glimepiride, insulin
Description: s.glucose control according to ESC guidelines
Study NCT00679237 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: weight reduction
Description: diet tips
Study NCT00385216 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Nicotine
Description: Nicotine nasal spray 3mg x 1 before surgery
Study NCT00385216 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo nasal spray 0mg x 1 before surgery
Study NCT02839759 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: TELLYHealth
Description: Educational videos and questions.
Study NCT04420715 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Training on coronary angiography using 3D coronary artery simulator
Description: Participants will have a test of coronary arteriography before and after training, compare the scores to analysis if the simulator training is effective.
Study NCT02377115 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: Tablet computer application
Description: Preoperatively, all study participants (entire cohort) will perform in the self-administered tablet computer-based tool to assess the risk of developing POD.
Study NCT03720054 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: MapTrek
Description: Our objective is to report activity levels in our virtual environment to veterans, thereby encouraging them first, to walk more every day, and second, to maintain these new increased levels of physical activity. MapTrek will also motivate veterans to accumulate less sedentary time.
Study NCT03720054 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Fitbit
Description: Fitbit Only
Study NCT02774031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Aisys with Et control
Study NCT02774031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Aisys conventional
Study NCT02774031 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Flow-i with ACG
Study NCT02774031 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Flow-i conventional
Study NCT00601419 — intervention group
Intervention type: DRUG
Intervention: Somatropin
Description: Genotropin® 12mg for Injection, Genotropin® MiniQuick for s.c. injection 0.6mg, Genotropin® MiniQuick for s.c. injection 1.0mg, Genotropin® MiniQuick for s.c. injection 1.4mg, Genotropin® 5.3mg.~Dosage, Frequency: According to Japanese LPD, The initial dosage is 0.021mg/kg/week as somatropin (genetical recombination) in 6-7 divided doses by s.c. route. The dosage is titrated by 0.084mg/kg/week at a maximum according to the patient's clinical symptoms, and administered in 6-7 divided doses in a week by s.c. route. The dosage may be adjusted according to patient's clinical symptoms and laboratory test results such as serum Insulin-like Growth Factor-I (IGF-I) concentrations. However, the maximum daily dosage shouldn't be higher than 1mg/day.~Duration: According to the protocol of A6281286, the duration of the investigation for findings regarding safety and efficacy of a patient is from the first drug administration to the 6 month after the first administration.
Study NCT03173677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Lipid Intake
Description: 90 grams whipping cream, 31.5 grams fat, 1.7 grams protein, and 2.25 grams carbohydrate
Study NCT03173677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Glucose intake
Description: 300 calories of glucose
Study NCT03173677 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Protein intake
Description: Isopure unflavored Whey proteins isolate (WPI) powder containing 26 grams per serving of 100% WPI, stripped of fat, carbs, fillers, sugars, and lactose
Study NCT04168333 — intervention group
Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: T101 Group
Description: Single Dose (SD) Cohort:~In each group, 3 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+9VP (Group1)/1.0E+10VP (Group2)/1.0E+11VP (Group 3) on D1.~Multiple Dose (MD) Cohort:~In each group, 9 of chronic hepatitis B patients will be subcutaneously injected with different dose level of T101 at 1.0E+10VP (Group1)/1.0E+11VP (Group2) on D1, D8, D15.
Study NCT04168333 — intervention group
Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Group
Description: Single Dose (SD) Cohort:~3 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1.~Multiple Dose (MD) Cohort:~6 of chronic hepatitis B patients will be subcutaneously injected with placebo on D1, D8, D15.
Study NCT01614197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus
Description: Dose will be assigned at study entry. Give IV over 30 minutes on days 1 and 8.
Study NCT01614197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Etoposide
Description: 100 mg/m2 IV over 1-2 hours daily x 5 on Days 1-5.
Study NCT01614197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: 440 mg/m2 IV daily x 5 on Days 1-5 given over 30-60 minutes.
Study NCT01614197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Methotrexate
Description: PATIENTS WITH CNS 1 COURSES 2, 4, 6, 8: Give intrathecally to patients who were CNS1 at study entry day 1 of each course at the doses listed below.~* Age 1 - 1.99 give 8 mg of methotrexate~* Age 2 - 2.99 give10 mg of methotrexate~* Age 3 - 8.99 give 12 mg of methotrexate~* Age ≥ 9 give 15 mg of methotrexate~PATIENTS WITH CNS 2 or 3 DISEASE~-COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age
Study NCT01614197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Hydrocortisone
Description: Given with Methotrexate and Cytarabine for patients with CNS 2 or 3 disease.~COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 6 and then weekly until the patient is CNS 1.~COURSES 2-8: Give intrathecally to patients who were CNS 3 at study entry on day 1 of each course.~* 8 mg for patients age 1-1.99~* 10 mg for patients age 2-2.99~* 12 mg for patients 3-8.99 years of age~* 15 mg for patients >9 years of age
Study NCT01614197 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cytarabine
Description: For Patients who are CNS1 COURSE 1: Give intrathecally to patients with CNS1 disease at the dose defined by age below on day 1 of course 1 if no other IT was given within 1 week of day 1 of course 1~* Age 1 - 1.99 give 30 mg of Cytarabine~* Age 2 - 2.99 give 50mg of Cytarabine~* Age ≥ 3 give 70 mg of Cytabine~For Patients with CNS 2 or 3 Disease COURSE 1: Give intrathecally to patients with CNS 2 or 3 disease at the doses defined by age below on day 1 if no other IT chemotherapy given within 1 week of day 1 of course 1. Then give weekly until the patient is CNS 1 or 2 (investigator discretion). No more than 5 weekly doses to be given in cycle 1.~COURSES 2-8: Give intrathecally to patients who were CNS 2or 3 at study entry on day 1 of each course.~* 16 mg for patients age 1-1.99~* 20 mg for patients age 2-2.99~* 24 mg for patients 3-8.99 years of age~* 30 mg for patients >9 years of age
Study NCT03970460 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Primary TKA with cemented modular metal-backed tibial implant
Description: Tibial implant will be done with a cemented implant
Study NCT03970460 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Primary TKA with uncemented trabecular metal
Description: Tibial implant will be done with a uncemented implant
Study NCT02907164 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Email invitation
Description: Receive emails encouraging them to sign up
Study NCT02907164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Email invitation
Description: Receive emails encouraging them to sign up
Study NCT02907164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Social norm
Description: Receive information about how many people have signed up
Study NCT02907164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Intrinsic, health motive
Description: Receive information about how the challenge helps people to stay fit in a fun way
Study NCT02907164 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Extrinsic, reward motive
Description: Receive information about how the challenge helps people to stay active and earn rewards
Study NCT00824356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1004723 (200mg)
Description: Intranasal antihistamine.
Study NCT00824356 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Equivalent to GSK1004723 in presentation etc.
Study NCT00824356 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: GSK1004723 (1000mg)
Description: Intranasal antihistamine.
Study NCT00824356 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: GSK1004723 (1000mg)
Description: Intranasal antihistamine.
Study NCT00971932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cetuximab
Description: The initial dose of cetuximab will be 400 milligram per square meter (mg/m\^2) as an intravenous (IV) infusion over 120 minutes. Subsequent weekly doses will be 250 mg/m\^2 as an IV infusion over 60 minutes.
Study NCT00971932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cisplatin/Carboplatin
Description: Subjects will receive 100 mg/m\^2 cisplatin as an IV infusion over 60 minutes on day 1 of each 3-week treatment cycle. If subject developed non-hematological toxicities to cisplatin, carboplatin (area under curve 5 \[AUC5\]) will be administered as an IV infusion over 60 to 120 minutes on Day 1 of each 3-week treatment cycle.
Study NCT00971932 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-Fluorouracil
Description: Subjects will receive 1000 mg/m\^2 per day 5-FU as a continuous IV infusion over 24 hours from day 1 to day 4 of each 3-week treatment cycle.
Study NCT04278040 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Melphalan
Description: Inhalations with low doses of Melphalan for 5 consequent days
Study NCT01664598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tocilizumab
Description: 8 mg/kg administered intravenously (IV) every 4 weeks for 104 weeks
Study NCT01094860 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nelarabine
Description: Starting dose 200 mg/m2 for 5 day continuous infusion administered via a central catheter, repeated every 28 days.